title: Evaluation at patients with ventricular arrhythmias and coronary artery disease of myocardial revascularization effects.
abstract: The aim of this study was to determine the relations between myocardial revascularization therapy--coronary artery bypass graft (CABG) and coronary angioplasty (PTCA)--and ventricular potentially malignant arrhythmia (VPMA) (coupled VPC, VPC > 10/hour, NSVT--Morganroth classification), in patients (pts) with stable CAD.
  
  
  METHODS
  765 patients with stable angina and ventricular potentially malignant arrhythmia were evaluated angiochoronarographically, echographically, by programmed electrical stimulation (PES), standard ECG, Holter ECG, radiologically, and by stress test. From 765 patients with CAD and VPMA 169 pts. (22.9% of cases) were revascularized, 77 pts. (10.06% of cases) by CABG surgery and 82 pts. (10.71% of cases) by PTCA with or without stenting.
  
  
  RESULTS
  From pts. with inducible sustained ventricular tachycardia by programmed electrical stimulation PES + (129 pts. 16.86% of cases), 19 pts. (2.5% of cases) were with CABG vs 9 pts. (1.17% of cases) with PTCA (p > 0.05). In 333 pts. with arrhythmogenic myocardic ischemia detected by Holter ECG/24 hours (Holter +) the distribution of myocardial revascularization was similar (40 pts., 5.22% of cases with CABG vs 46 pts., 6.01% of cases with PTCA) (p > 0.05). The study included 225 pts. with positive stress test, 45 pts. were revascularized, 18 pts. (2.35% of cases) with CABG and 27 pts. (3.52% of cases) with PTCA (p > 0.05). Revascularized pts. represent an increased percent with prior myocardial infarction in the subgroup with CABG vs. PTCA (39% of cases, p < 0.05 vs. 25% of cases, p < 0.05). Revascularized pts. presented similar distributions of VPMA in subgroups with CABG and PTCA.
  
  
  CONCLUSIONS
  VPMA was not influenced by myocardial revascularization, CABG or PTCA, the incidence being similar (50.94% vs 47.2%; p < 0.05) with pts. drug treated.
authors.affiliation: Army's Center for Cardiovascular Disease, Bucharest, Romania. liviuchiriac10@yahoo.com
authors.forename: L
authors.initials: L
authors.lastname: Chiriac
authors.forename: S
authors.initials: S
authors.lastname: Dumitrescu
authors.forename: M
authors.initials: M
authors.lastname: Samoilă
authors.forename: G
authors.initials: G
authors.lastname: Cristian
authors.forename: V
authors.initials: V
authors.lastname: Murgu
authors.forename: Florina
authors.initials: F
authors.lastname: Pinte
authors.forename: I
authors.initials: I
authors.lastname: Mocanu
authors.forename: V
authors.initials: V
authors.lastname: Greere
authors.forename: C
authors.initials: C
authors.lastname: Jurcuţ
authors.forename: I
authors.initials: I
authors.lastname: Droc
authors.forename: I
authors.initials: I
authors.lastname: Tintoiu
authors.forename: A
authors.initials: A
authors.lastname: Câmpeanu
mesh_terms: D000328:Adult; D000368:Aged; D015906:Angioplasty, Balloon, Coronary; D002317:Cardiovascular Agents / Q000627:therapeutic use; D015331:Cohort Studies; D001026:Coronary Artery Bypass; D003324:Coronary Artery Disease / Q000150:complications / Q000503:physiopathology* / Q000628:therapy*; D004562:Electrocardiography; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D015607:Stents; D017180:Tachycardia, Ventricular / Q000150:complications / Q000175:diagnosis / Q000628:therapy*; D016896:Treatment Outcome
chemical_list: D002317:Cardiovascular Agents